^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Tafinlar (dabrafenib)

    i
    Other names: GSK2118436, GSK436, 2118436, DRB 436, GSK-2118436A, GSK2118436A, GSK-2118436, GSK 2118436, DRB-436, DRB436, GSK 2118436A, GSK-436, GSK 436
    Company:
    BeOne Medicines, Novartis
    Drug class:
    BRAF inhibitor
    Related drugs:
    Apply
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (NCI-MATCH) (NCT02465060)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    08/17/2015
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    MSI • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • cisplatin • Mekinist (trametinib) • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • capecitabine • Talzenna (talazoparib) • Piqray (alpelisib) • enzalutamide • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • eribulin mesylate • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • methotrexate • Truqap (capivasertib) • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • carmustine • Erivedge (vismodegib) • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • melphalan • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • fludarabine IV • Zynyz (retifanlimab-dlwr) • avadomide (CC-122) • Ostarine (enobosarm) • vistusertib (AZD2014) • mesna • Myocet (non-pegylated liposomal doxorubicin) • vinblastine • lorvotuzumab mertansine (IMGN901) • Xofigo (radium Ra-223 dichloride) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ieramilimab (LAG525) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • levoleucovorin calcium • methotrexate IV • Pertuvia (pertuzumab biosimilar) • sapitinib (AZD8931) • Vasforda (bevacizumab biosimilar)
    Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion (NCT06739395)
    Phase 2
    Tianjin Medical University Second Hospital
    Recruiting
    Last update posted :
    12/18/2024
    Initiation :
    11/01/2024
    Primary completion :
    12/31/2026
    Completion :
    05/01/2027
    BRAF
    |
    Lynparza (olaparib) • Mekinist (trametinib) • Ibrance (palbociclib) • Tafinlar (dabrafenib) • Focus V (anlotinib) • temozolomide • Lenvima (lenvatinib) • Piqray (alpelisib) • pazopanib • Epidaza (chidamide) • Trodelvy (sacituzumab govitecan-hziy) • vebreltinib (APL-101)
    A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma (COMBI-i) (NCT02967692)
    Phase 3
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    02/17/2017
    Primary completion :
    08/11/2020
    Completion :
    08/26/2024
    PD-L1 • CD8
    |
    PD-L1 expression • BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • spartalizumab (PDR001)
    A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer (NCT04294160)
    Phase 1
    Novartis Pharmaceuticals
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    07/22/2020
    Primary completion :
    10/11/2024
    Completion :
    10/11/2024
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001) • naporafenib (ERAS-254) • batoprotafib (TNO155) • rineterkib (LTT462)
    Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma (NCI-2013-02103) (NCT01989585)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/16/2024
    Initiation :
    03/24/2014
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    PTEN • BCL2
    |
    BRAF V600E • BRAF mutation • BRAF V600 • PTEN mutation • BRAF V600K
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • navitoclax (ABT 263)
    A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma (NCT03091257)
    Phase 1
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    04/16/2024
    Initiation :
    06/21/2017
    Primary completion :
    09/15/2024
    Completion :
    09/15/2024
    KRAS • NRAS
    |
    KRAS mutation • BRAF mutation
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy (NCT06362694)
    Phase 2
    Saint Petersburg State University, Russia
    Recruiting
    Last update posted :
    04/12/2024
    Initiation :
    03/25/2024
    Primary completion :
    03/25/2026
    Completion :
    06/25/2026
    PD-L1
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST) (NCT04116541)
    Phase 2
    Centre Leon Berard
    Recruiting
    Last update posted :
    03/27/2024
    Initiation :
    01/28/2020
    Primary completion :
    02/01/2026
    Completion :
    11/01/2026
    KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK
    |
    KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)
    JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations (NCT04418167)
    Phase 1
    JS InnoPharm, LLC
    Suspended
    Last update posted :
    02/02/2024
    Initiation :
    06/18/2020
    Primary completion :
    06/30/2024
    Completion :
    12/17/2024
    MAP2K1 • NF1 • RASA1
    |
    BRAF V600E • BRAF V600K
    |
    Tafinlar (dabrafenib) • JSI-1187
    Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma (NCT02367859)
    Phase 2
    Stanford University
    Completed
    Last update posted :
    01/30/2024
    Initiation :
    07/17/2017
    Primary completion :
    11/05/2018
    Completion :
    06/26/2019
    ALK • RAF1
    |
    BRAF V600E • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)
    A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study) (NCT05182931)
    Phase 2
    Olivia Newton-John Cancer Research Institute
    Recruiting
    Last update posted :
    10/31/2023
    Initiation :
    07/14/2022
    Primary completion :
    12/30/2024
    Completion :
    12/30/2025
    NRAS
    |
    BRAF V600E • BRAF V600
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib)